{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:16:35Z","timestamp":1793229395115,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-71496-y","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T03:35:17Z","timestamp":1725420917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Quantitative comparison of automated OCT and conventional FAF-based geographic atrophy measurements in the phase 3 OAKS\/DERBY trials"],"prefix":"10.1038","volume":"14","author":[{"given":"Julia","family":"Mai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor S.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Dieter","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Sadeghipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Foos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"McKeown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrvoje","family":"Bogunovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Schmidt-Erfurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"71496_CR1","unstructured":"Apellis. FDA Approves SYFOVRE\u2122 (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness. https:\/\/investors.apellis.com\/news-releases\/news-release-details\/fda-approves-syfovretm-pegcetacoplan-injection-first-and-only (2023)."},{"key":"71496_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","volume":"127","author":"DS Liao","year":"2020","unstructured":"Liao, D. S. et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: A randomized phase 2 trial. Ophthalmology 127, 186\u2013195. https:\/\/doi.org\/10.1016\/j.ophtha.2019.07.011 (2020).","journal-title":"Ophthalmology"},{"key":"71496_CR3","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/s0140-6736(23)01520-9","volume":"402","author":"JS Heier","year":"2023","unstructured":"Heier, J. S. et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): Two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet 402, 1434\u20131448. https:\/\/doi.org\/10.1016\/s0140-6736(23)01520-9 (2023).","journal-title":"Lancet"},{"key":"71496_CR4","unstructured":"Astellas. Iveric Bio Receives U.S. FDA Approval for IZERVAY\u2122 (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy (2023)."},{"key":"71496_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01583-0","author":"AM Khanani","year":"2023","unstructured":"Khanani, A. M. et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet https:\/\/doi.org\/10.1016\/s0140-6736(23)01583-0 (2023).","journal-title":"Lancet"},{"key":"71496_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000330420","volume":"226","author":"AP G\u00f6bel","year":"2011","unstructured":"G\u00f6bel, A. P., Fleckenstein, M., Schmitz-Valckenberg, S., Brinkmann, C. K. & Holz, F. G. Imaging geographic atrophy in age-related macular degeneration. Ophthalmologica 226, 182\u2013190. https:\/\/doi.org\/10.1159\/000330420 (2011).","journal-title":"Ophthalmologica"},{"key":"71496_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/iae.0000000000001392","volume":"37","author":"DS Boyer","year":"2017","unstructured":"Boyer, D. S., Schmidt-Erfurth, U., van Lookeren Campagne, M., Henry, E. C. & Brittain, C. The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target. Retina 37, 819\u2013835. https:\/\/doi.org\/10.1097\/iae.0000000000001392 (2017).","journal-title":"Retina"},{"key":"71496_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","volume":"125","author":"M Fleckenstein","year":"2018","unstructured":"Fleckenstein, M. et al. The progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology 125, 369\u2013390. https:\/\/doi.org\/10.1016\/j.ophtha.2017.08.038 (2018).","journal-title":"Ophthalmology"},{"key":"71496_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.oret.2020.07.006","volume":"5","author":"SC Cleland","year":"2021","unstructured":"Cleland, S. C. et al. Quantification of geographic atrophy using spectral domain OCT in age-related macular degeneration. Ophthalmol. Retina 5, 41\u201348. https:\/\/doi.org\/10.1016\/j.oret.2020.07.006 (2021).","journal-title":"Ophthalmol. Retina"},{"key":"71496_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/eye.2016.227","volume":"31","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth, U., Klimscha, S., Waldstein, S. M. & Bogunovi\u0107, H. A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration. Eye (Lond) 31, 26\u201344. https:\/\/doi.org\/10.1038\/eye.2016.227 (2017).","journal-title":"Eye (Lond)"},{"key":"71496_CR11","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.ophtha.2011.01.043","volume":"118","author":"RG Sayegh","year":"2011","unstructured":"Sayegh, R. G. et al. A systematic comparison of spectral-domain optical coherence tomography and fundus autofluorescence in patients with geographic atrophy. Ophthalmology 118, 1844\u20131851. https:\/\/doi.org\/10.1016\/j.ophtha.2011.01.043 (2011).","journal-title":"Ophthalmology"},{"key":"71496_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2018.07.004","volume":"67","author":"U Schmidt-Erfurth","year":"2018","unstructured":"Schmidt-Erfurth, U., Sadeghipour, A., Gerendas, B. S., Waldstein, S. M. & Bogunovi\u0107, H. Artificial intelligence in retina. Prog. Retin. Eye Res. 67, 1\u201329. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.07.004 (2018).","journal-title":"Prog. Retin. Eye Res."},{"key":"71496_CR13","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.oret.2022.05.030","volume":"6","author":"S Riedl","year":"2022","unstructured":"Riedl, S. et al. The effect of pegcetacoplan treatment on photoreceptor maintenance in geographic atrophy monitored by artificial intelligence-based OCT analysis. Ophthalmol. Retina 6, 1009\u20131018. https:\/\/doi.org\/10.1016\/j.oret.2022.05.030 (2022).","journal-title":"Ophthalmol. Retina"},{"key":"71496_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.08.003","author":"WD Vogl","year":"2022","unstructured":"Vogl, W. D. et al. Predicting topographic disease progression and treatment response of pegcetacoplan in geographic atrophy quantified by deep learning. Ophthalmol. Retina https:\/\/doi.org\/10.1016\/j.oret.2022.08.003 (2022).","journal-title":"Ophthalmol. Retina"},{"key":"71496_CR15","doi-asserted-by":"crossref","unstructured":"Lachinov, D., Seeb\u00f6ck, P., Mai, J., Schmidt-Erfurth, U. & Bogunovi\u0107, H. Projective Skip-Connections for Segmentation Along a Subset of Dimensions in Retinal OCT (2021).","DOI":"10.1007\/978-3-030-87193-2_41"},{"key":"71496_CR16","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1038\/s41598-020-62329-9","volume":"10","author":"JI Orlando","year":"2020","unstructured":"Orlando, J. I. et al. Automated quantification of photoreceptor alteration in macular disease using optical coherence tomography and deep learning. Sci. Rep. 10, 5619. https:\/\/doi.org\/10.1038\/s41598-020-62329-9 (2020).","journal-title":"Sci. Rep."},{"key":"71496_CR17","doi-asserted-by":"publisher","first-page":"7028","DOI":"10.1038\/s41598-023-34139-2","volume":"13","author":"J Mai","year":"2023","unstructured":"Mai, J. et al. Clinical validation for automated geographic atrophy monitoring on OCT under complement inhibitory treatment. Sci. Rep. 13, 7028. https:\/\/doi.org\/10.1038\/s41598-023-34139-2 (2023).","journal-title":"Sci. Rep."},{"key":"71496_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/iovs.10-5619","volume":"52","author":"S Schmitz-Valckenberg","year":"2011","unstructured":"Schmitz-Valckenberg, S., Fleckenstein, M., G\u00f6bel, A. P., Hohman, T. C. & Holz, F. G. Optical coherence tomography and autofluorescence findings in areas with geographic atrophy due to age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 52, 1\u20136. https:\/\/doi.org\/10.1167\/iovs.10-5619 (2011).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"71496_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ajo.2014.05.026","volume":"158","author":"C Simader","year":"2014","unstructured":"Simader, C. et al. A longitudinal comparison of spectral-domain optical coherence tomography and fundus autofluorescence in geographic atrophy. Am. J. Ophthalmol. 158, 557-566.e551. https:\/\/doi.org\/10.1016\/j.ajo.2014.05.026 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"71496_CR20","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.oret.2018.01.019","volume":"2","author":"L Shen","year":"2018","unstructured":"Shen, L., Liu, F., Grossetta Nardini, H. & Del Priore, L. V. Natural history of geographic atrophy in untreated eyes with nonexudative age-related macular degeneration: A systematic review and meta-analysis. Ophthalmol. Retina 2, 914\u2013921. https:\/\/doi.org\/10.1016\/j.oret.2018.01.019 (2018).","journal-title":"Ophthalmol. Retina"},{"key":"71496_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ajo.2022.06.023","volume":"244","author":"J Mai","year":"2022","unstructured":"Mai, J. et al. Comparison of fundus autofluorescence versus optical coherence tomography-based evaluation of the therapeutic response to pegcetacoplan in geographic atrophy. Am. J. Ophthalmol. 244, 175\u2013182. https:\/\/doi.org\/10.1016\/j.ajo.2022.06.023 (2022).","journal-title":"Am. J. Ophthalmol."},{"key":"71496_CR22","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.oret.2022.03.017","volume":"6","author":"SB Velaga","year":"2022","unstructured":"Velaga, S. B., Nittala, M. G., Hariri, A. & Sadda, S. R. Correlation between fundus autofluorescence and en face OCT measurements of geographic atrophy. Ophthalmol. Retina 6, 676\u2013683. https:\/\/doi.org\/10.1016\/j.oret.2022.03.017 (2022).","journal-title":"Ophthalmol. Retina"},{"key":"71496_CR23","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.oret.2019.07.016","volume":"3","author":"DL Wang","year":"2019","unstructured":"Wang, D. L. et al. Outer retinal thickness and fundus autofluorescence in geographic atrophy. Ophthalmol. Retina 3, 1035\u20131044. https:\/\/doi.org\/10.1016\/j.oret.2019.07.016 (2019).","journal-title":"Ophthalmol. Retina"},{"key":"71496_CR24","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1097\/iae.0000000000002182","volume":"38","author":"M Li","year":"2018","unstructured":"Li, M. et al. Histology of geographic atrophy secondary to age-related macular degeneration: A multilayer approach. Retina 38, 1937\u20131953. https:\/\/doi.org\/10.1097\/iae.0000000000002182 (2018).","journal-title":"Retina"},{"key":"71496_CR25","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/iae.0000000000002461","volume":"39","author":"M Li","year":"2019","unstructured":"Li, M. et al. Clinicopathologic correlation of geographic atrophy secondary to age-related macular degeneration. Retina 39, 802\u2013816. https:\/\/doi.org\/10.1097\/iae.0000000000002461 (2019).","journal-title":"Retina"},{"key":"71496_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1167\/iovs.61.6.11","volume":"61","author":"GS Reiter","year":"2020","unstructured":"Reiter, G. S. et al. Subretinal drusenoid deposits and photoreceptor loss detecting global and local progression of geographic atrophy by SD-OCT imaging. Investig. Ophthalmol. Vis. Sci. 61, 11. https:\/\/doi.org\/10.1167\/iovs.61.6.11 (2020).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"71496_CR27","doi-asserted-by":"publisher","first-page":"Amd12","DOI":"10.1167\/iovs.17-23203","volume":"59","author":"M Lindner","year":"2018","unstructured":"Lindner, M. et al. Local progression kinetics of geographic atrophy in age-related macular degeneration are associated with atrophy border morphology. Investig. Ophthalmol. Vis. Sci. 59, Amd12-amd18. https:\/\/doi.org\/10.1167\/iovs.17-23203 (2018).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"71496_CR28","first-page":"919","volume":"64","author":"U Schmidt-Erfurth","year":"2023","unstructured":"Schmidt-Erfurth, U. et al. Therapeutic effect of pegcetacoplan on retinal pigment epithelium (RPE) and photoreceptor (PR) integrity in geographic atrophy (GA) in the phase III OAKS and DERBY trials. Investig. Ophthalmol. Vis. Sci. 64, 919\u2013919 (2023).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"71496_CR29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ajo.2016.06.006","volume":"168","author":"A Takahashi","year":"2016","unstructured":"Takahashi, A. et al. Photoreceptor damage and reduction of retinal sensitivity surrounding geographic atrophy in age-related macular degeneration. Am. J. Ophthalmol. 168, 260\u2013268. https:\/\/doi.org\/10.1016\/j.ajo.2016.06.006 (2016).","journal-title":"Am. J. Ophthalmol."},{"key":"71496_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jcjo.2013.03.022","volume":"48","author":"E Pilotto","year":"2013","unstructured":"Pilotto, E. et al. Microperimetry, fundus autofluorescence, and retinal layer changes in progressing geographic atrophy. Can. J. Ophthalmol. 48, 386\u2013393. https:\/\/doi.org\/10.1016\/j.jcjo.2013.03.022 (2013).","journal-title":"Can. J. Ophthalmol."},{"key":"71496_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ajo.2016.05.007","volume":"168","author":"AH Hariri","year":"2016","unstructured":"Hariri, A. H., Tepelus, T. C., Akil, H., Nittala, M. G. & Sadda, S. R. Retinal sensitivity at the junctional zone of eyes with geographic atrophy due to age-related macular degeneration. Am. J. Ophthalmol. 168, 122\u2013128. https:\/\/doi.org\/10.1016\/j.ajo.2016.05.007 (2016).","journal-title":"Am. J. Ophthalmol."},{"key":"71496_CR32","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1136\/bjophthalmol-2014-305195","volume":"98","author":"RG Sayegh","year":"2014","unstructured":"Sayegh, R. G. et al. A systematic correlation of morphology and function using spectral domain optical coherence tomography and microperimetry in patients with geographic atrophy. Br. J. Ophthalmol. 98, 1050\u20131055. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305195 (2014).","journal-title":"Br. J. Ophthalmol."},{"key":"71496_CR33","unstructured":"Stealth, B. StealthBio Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA on the Development of Elamipretide in Patients with Dry Age-related Macular Degeneration. https:\/\/www.prnewswire.com\/news-releases\/stealth-biotherapeutics-announces-positive-end-of-phase-2-meeting-with-fda-on-the-development-of-elamipretide-in-patients-with-dry-age-related-macular-degeneration-301848690.html (2023)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71496-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71496-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71496-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T03:36:49Z","timestamp":1725421009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71496-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["71496"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-71496-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The OAKS and DERBY trials were conducted by Apellis Pharmaceuticals and our work was in part supported by an Apellis research grant. Financial Disclosures:  Julia Mai: Consultancy: Apellis, Roche  Gregor S. Reiter: Contract Research: RetInSight, Consultancy: Apellis, Bayer, Roche  Sophie Riedl: No financial disclosures  Wolf-Dieter Vogl: Employment RetInSight  Amir Sadeghipour: Employment RetInSight  Emma Foos: Employment Apellis  Alex McKeown: Employment Apellis  Hrvoje Bogunovic: Contract Research to the Medical University of Vienna: Apellis, Heidelberg Engineering  Ursula Schmidt-Erfurth: Scientific Consultant: Apellis, Aviceda, Complementtherapeutix, Heidelberg Engineering, Novartis, ONL, RetInSight, Roche, Topcon Contract Research to the Medical University of Vienna: Apellis, Genentech, Kodiak.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20531"}}